

From: [REDACTED]
Sent: 13 March 2018 22:50
To: response
Cc: 'hui.ou'; 'Xiao (Patricia) Yang'
Subject: FW: 香港上市规则修订意见

Dear Sir/Madam,

Please find our response/feedback on the new HKEX biotech platform/initiative document:

- 1, 92 条, 要求根据生物科技章节上市的公司股份代号结尾加上独特的股份标记 B
企业财务指标达到主板或者创业板盈利测试要求之后, 相关的转板或者去除股份标记 B 的政策指南没有看到
- 2, 18A.04, 第 (2) 条, (f) 披露与核心产品有关的所有重要安全数据
建议在不会涉及商业机密的前提下
- 3, 18A.03, 第 (4) 条, 该等开支应主要包括 (a) 一般行政及运营开支 (包括任何生产成本)
建议修改成与研发相关的生产成本, 而剔除掉销售产品相关的生产成本, 因为有些公司如果下一年有产品上市销售的话, 会产生大量的生产成本支出, 然而其当期产品收入一般情况下是可以覆盖其支出的, 如果在期初就要求企业留存整年销售产品所需的的生产成本现金支出就会显得不那么公平和合理。
4. 首次公开招股资金用途:
集资主要用于研发, 及商业化, 以将核心产品推出市面

Shoufeng Li



Aucta Pharmaceuticals, Inc.

Address: 675 US Route One, North Brunswick, NJ 08902

<http://www.auctapharma.com>

This e-mail or attachments contain confidential or privileged information, which is only intended for personnel or institutions designated by the above e-mail address. Except the recipient, any person or institution read, forward or take any action based on the information is prohibited. If you have received this e-mail by mistake, please contact the sender and delete the e-mail.